Xiequn L. Chen

Beijing, 100071, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications

Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma

Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma

Journal: Zhonghua yi xue za zhi
Published: May 07, 2026

Autologous hematopoietic stem cell transplantation with TBE conditioning in patients with primary central nervous system lymphoma

Autologous hematopoietic stem cell transplantation with TBE conditioning in patients with primary central nervous system lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 17, 2025

PARP1 inhibitor niraparib exerts synergistic antimyeloma effect with bortezomib through inducing DNA damage and inhibiting DNA repair.

PARP1 inhibitor niraparib exerts synergistic antimyeloma effect with bortezomib through inducing DNA damage and inhibiting DNA repair.

Journal: Free radical biology & medicine
Published: October 31, 2024

Analysis of the efficacy and safety of bone disease treatment in patients with newly diagnosed multiple myeloma treated with denosumab or zoledronic acid

Analysis of the efficacy and safety of bone disease treatment in patients with newly diagnosed multiple myeloma treated with denosumab or zoledronic acid

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: July 01, 2024

Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey.

Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey.

Journal: Acta haematologica
Published: April 29, 2024

Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma

Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 19, 2024

Autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma with severe renal impairment: a report of 5 cases and literature review

Autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma with severe renal impairment: a report of 5 cases and literature review

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: September 25, 2023

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 19, 2023

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

Journal: BMC cancer
Published: April 12, 2023

2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy.

2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy.

Journal: Chinese medical journal
Published: June 22, 2022

Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.

Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.

Journal: Acta haematologica
Published: May 19, 2022

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.

Journal: BMC medicine
Published: December 23, 2021
Showing 1-12 of 45

Last Updated: 09/26/2026